Company / Working Capital
Xenetic Biosciences, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$7.1M
FY2025
5-year range
$5.7M / $17.3M
FY2021-FY2025
Trend
+24.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital returned to growth in FY2025 after 3 years of decline, reaching $7M.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of -9.1%.
Declined from $9M to $7M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -17.4%
- 5-Year CAGR
- -9.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -9.1%, indicating a declining trend.
- In FY2025, working capital increased 24.4% year-over-year.
- Peak working capital was recorded in FY2021.
- Lowest working capital in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.1M | +24.4% |
| FY2024 | $5.7M | -35.1% |
| FY2023 | $8.8M | -30.2% |
| FY2022 | $12.6M | -27.3% |
| FY2021 | $17.3M | +51.3% |
| FY2020 | $11.4M | +18.2% |
| FY2019 | $9.7M | +2484.0% |
| FY2018 | -$405.8K | -110.3% |
| FY2017 | $3.9M | -39.1% |
| FY2016 | $6.5M | +272.0% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026